Erratum: Increased plasma levels of soluble TNF receptors 1 and 2 in bipolar depression and impact of lithium treatment (Human Psychopharmacology (2015) 30 (52-56) DOI: 10.1002/hup.2450);Increased plasma levels of soluble TNF receptors 1 and 2 in bipolar depression and impact of lithium treatment

Human Psychopharmacology

Volumn 30, Issue 1, 2015, Pages 52-56

  Teixeira, Antonio L ^a   De Souza, Rafael T ^b   Zanetti, Marcus V ^b   Brunoni, Andre R ^b   Busatto, Geraldo F ^b   Zarate, Carlos A ^c   Gattaz, Wagner F ^b   Machado Vieira, Rodrigo ^b,c  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Bipolar depression; Bipolar disorder; Lithium; sTNFR1; sTNFR2

Indexed keywords

BENZODIAZEPINE; LITHIUM CARBONATE; MOOD STABILIZER; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 1; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; ZOLPIDEM; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II;

ADULT; ARTICLE; BIPOLAR DEPRESSION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; INSOMNIA; LITHIUM BLOOD LEVEL; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE; YOUNG MANIA RATING SCALE; BIPOLAR DISORDER; BLOOD; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PHLEBOTOMY; PSYCHIATRIC STATUS RATING SCALES; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

ADULT; BIPOLAR DISORDER; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LITHIUM CARBONATE; MALE; PHLEBOTOMY; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84920714164     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2493     Document Type: Erratum

References (31)

1. Barbosa IG, Huguet RB, Mendonna VA, et al. 2011. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci 261(2): 139-143.
2. Barbosa IG, Rocha NP, Huguet RB, et al. 2012. Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. J Affect Disord 137(1-3): 151-155.
3. Barbosa IG, Machado-Vieira R, Soares JC, Teixeira AL. 2014. The immunology of bipolar disorder. Neuroimmunomodulation 21(2-3): 117-122.
4. Brietzke E, Kapczinski F. 2008. TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 32(6): 1355-1361.
5. Brown NC, Andreazza AC, Young LT. 2014. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res pii: S0165-1781(14)00282-0. DOI: 10.1016/j.psychres.2014.04.005
6. Brunoni AR, Machado-Vieira R, Zarate CA, et al. 2014. Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial. Psychopharmacology (Berl) 231(7): 1315-1323.
7. Coelho FM, Reis HJ, Nicolato R, et al. 2008. Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia. Neuroimmunomodulation 15(2): 140-144.
8. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. 1995. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 54(1): 1-8.
9. Doganavsargil-Baysal O, Cinemre B, Aksoy UM, et al. 2013. Levels of TNF-alpha, soluble TNF receptors (sTNFR1, sTNFR2), and cognition in bipolar disorder. Hum Psychopharmacol 28(2): 160-167.
10. First MB, Spitzer RL, Gibbon M, Williams JBW. 1997. Structured Clinical Interview for DSM-IV Clinical Version (SCID-I/CV). American Psychiatric Press: Washington, DC.
11. Gigante AD, Young LT, Yatham LN, et al. 2011. Morphometric post-mortem studies in bipolar disorder: possible association with oxidative stress and apoptosis. Int J Neuropsychopharmacol 14(8): 1075-1089.
12. Grassi-Oliveira R, Brietzke E, Pezzi JC, Lopes RP, Teixeira AL, Bauer ME. 2009. Increased soluble tumor necrosis factor-alpha receptors in patients with major depressive disorder. Psychiatry Clin Neurosci 63(2): 202-208.
13. Haarman BC, Riemersma-Van der Lek RF, de Groot JC, et al. 2014. Neuroinflammation in bipolar disorder - A [11C]-(R)-PK11195 positron emission tomography study. Brain Behav Immun pii: S0889-1591(14)00082-8. doi: 10.1016/j.bbi.2014.03.016
14. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
15. Hannestad J, DellaGioia N, Bloch M. 2011. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36(12): 2452-2459.
16. Hope S, Dieset I, Agartz I, et al. 2011. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res 45(12): 1608-1616.
17. Kapczinski F, Dal-Pizzol F, Teixeira AL, et al. 2011. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res 45: 156-161.
18. Li Z, Qi D, Chen J, et al. 2013. Venlafaxine inhibits upregulation of plasma tumor necrosis factor-alpha (TNF-alpha in the Chinese patients in major depressive disorder: a prospective longitudinal study. Psychoneuroendocrinology 38(1): 107-114.
19. Machado-Vieira R, Manji HK, Zarate CA Jr. 2009. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 11(Suppl 2): 92-109.
20. Machado-Vieira R, Soeiro-De-Souza MG, Richards EM, Teixeira AL, Zarate CA Jr. 2014. Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach. World J Biol Psychiatry 15(2): 84-95.
21. McAfoose J, Baune BT. 2009. Evidence for a cytokine model of cognitive functions. Neurosci Biobehav Rev 33: 355-366.
22. Munkholm K, Braüner JV, Kessing LV, Vinberg M. 2013a. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res 47(9): 1119-1133.
23. Munkholm K, Vinberg M, Vedel Kessing L. 2013b. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord 144(1-2): 16-27.
24. Nassar A, Azab AN. 2014. Effects of Lithium on Inflammation. ACS Chem Neurosci. [Epub ahead of print] PMID: 24803181. DOI: 10.1021/cn500038f.
25. O' Brien SM, Scully P, Scott LV, Dinan TG. 2006. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord 90: 263-267.
26. Ortiz-Dominguez A, Hernandez ME, Berlanga C, et al. 2007. Immune variations in bipolar disorder: phasic differences. Bipolar Disord 9: 596-602.
27. Rocha NP, Teixeira AL, Scalzo PL, et al. 2014. Palotder: phasic difPlasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease. Mov Disord 29(4): 527-531.
28. Teixeira AL, Barbosa IG, Machado-Vieira R, Rizzo LB, Wieck A, Bauer ME. 2013. Novel biomarkers for bipolar disorder. Expert Opin Med Diagn 7(2): 147-159.
29. Tsai SY, Chung KH, Wu JY, Kuo CJ, Lee HC, Huang SH. 2012. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord 136(1-2): 110-116.
30. Yatham LN, Kennedy SH, Parikh SV, et al. 2013. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 15(1): 1-44.
31. Young RC, Biggs, JT, Ziegler VE, Meyer DA. 1978. A rating scale for mania: reliability, validity, and sensitivity. Brit J Psychiatry 133: 429-435.